Skip to main content
. 2021 Apr;10(4):1873–1888. doi: 10.21037/tlcr-21-192

Table 1. Baseline characteristics of patients.

Characteristics Patient
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Age 63 67 63 78 73 60 73 73 52 55 72 67 57 70 78 63 57 70 48 72
Gender M FE FE M M M M FE M FE FE M FE FE M FE FE M FE M
Smoking Yes NO NO YES YES Yes NO NO YES NO NO NO NO NO YES NO NO NO NO YES
Pathologic type AD AD. AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD
Gene type
   EGFR 19 19 19 21 21 21 20 21 21 19 21 21 19 21 21 21 19 21 19 19
   Detection Arms Arms NGS Arms NGS Arms NGS NGS Arms NGS Arms NGS Arms Arms NGS Arms Arms NGS NGS NGS
   Method PCR PCR PCR PCR PCR PCR PCR PCR PCR PCR
   Samples Tumor Tumor Blood Tumor Tumor Tumor Tumor Blood Tumor Blood Tumor Blood Tumor Tumor Blood Blood Tumor Blood Tumor Blood
Therapy (response)
   First line GE GE GE IC IC IC GE GE GE GE GE GE GE IC IC IC GE GE IC GE
(PR) (SD) (PR) (PR) (PR) (SD) (SD) (SD) (SD) (PR) (SD) (SD) (PR) (PR) (PR) (SD) (SD) (SD) (SD) (PR)
   1.5-line GE and AN GE and AN GE and AN IC and AN IC and AN IC and AN GE and AN GE and AN GE and AN GE and AN GE and AN GE and AN GE and AN IC and AN IC and AN IC and AN Ge and AN Ge and AN IC and AN Ge and AN
VEGF (pg/mL)
   Pre- anlotinib 191.4 188.3 250.5 308.6
   Post-anlotinib 148.4 109.4 177.6 297.7
NSE (pg/mL)
   Pre-anlotinib 24.54 27.07 19.16 14.63 18.56 14.14 10.28 14.23 19.87 12.03 19.17 14.63 14.39 14.28
   Post-anlotinib 16.54 15.83 14.97 10.92 16.13 18 15.9 15.37 17.55 17.04 20.47 14.58 15.07 16.9
CEA (μg/mL)
   Pre- anlotinib 81.49 38.93 2.16 46.48 79.31 51.64. 5.27 10.29 2.59 12.9 5.16 7.9 90.88 23.07 501.8 35.64. 8.3 21.29 80.84 34.9
   Post- anlotinib 55.66 19.25 1.44 15.78 20.79 48.39 3.01 9.76 3.9 9 7.07 3.74 53.94 24.89 281.7 33.39 8.44 18.99 7.66 37
Adverse events
   Hypertension Grade 1 Grade 3 Grade 3 Grade 3 Grade 3 Grade 1 Grade 3 Grade 3 Grade 3 Grade 3
   Hand-foot Grade 2–3 Grade 1 Grade 1 Grade 2–3 Grade 1 Grade 1
   Diarrhea Grade 1 Grade 3 Grade 1 Grade 1 Grade 3 Grade 1
   Fatigue Grade 1 Grade 1 Grade 1 Grade 1 Grade 1 Grade 1 Grade 1 Grade 1
   Oral ulcers Grade 1–2 Grade 1 Grade 1 Grade 1 Grade 1–2 Grade 1 Grade 1 Grade 1
   Anorexia Grade 1 Grade 1 Grade 1 Grade 1

M, male; FE, female; AD, adenocarcinoma; GE, gefitinib; AN, anlotinib; IC, icotinib; CEA, carcinoembryonic antigen; PD, progressive disease; PR, partial response; SD, stable disease.